PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-42.34%
Cash & equivalents declining -42.34% while RVPH's grows 95.93%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-42.34%
Below half of RVPH's 95.93%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.91%
Other current assets growth 50-75% of RVPH's -54.11%. Bruce Berkowitz notes fewer expansions. Possibly simpler working capital.
-41.98%
Below half of RVPH's 72.84%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-100.00%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Other Non-Current Assets Growth compared to RVPH's zero value, indicating worse performance.
-100.00%
Both RVPH and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-42.01%
Below half of RVPH's 64.40%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-48.73%
Less than half of RVPH's 5.25%. David Dodd sees a more disciplined AP approach or lower volume.
-46.67%
Similar yoy changes to RVPH's -49.51%. Walter Schloss finds a parallel approach to short-term funding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.33%
Less than half of RVPH's 8.21%. David Dodd sees fewer expansions in other current obligations.
-39.56%
Less than half of RVPH's 4.94%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39.56%
Less than half of RVPH's 4.83%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.24%
Below half RVPH's -3.55%. Michael Burry suspects major net losses or high dividends vs. competitor.
99.72%
Higher AOCI Growth compared to RVPH's zero value, indicating worse performance.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to RVPH's zero value, indicating worse performance.
-51.92%
Below half RVPH's 89.71%. Michael Burry sees potential underperformance in building shareholder capital.
-42.01%
Below half RVPH's 64.40%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-46.67%
Similar yoy changes to RVPH's -49.51%. Walter Schloss notes parallel total debt strategies.
42.23%
Less than half of RVPH's -102.37%. David Dodd sees better deleveraging or stronger cash buildup than competitor.